β- d -Arabinofuranose-configured Cyclitol Aziridines as Selective, Brain-penetrant Covalent GBA2 Inhibitors
Journal of the American Chemical Society · 2026
DOI: 10.1021/jacs.6c09754 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Chemical Society, 2026. Verfasst von Rob F Lammers und 21 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Medical Biochemistry and Bio-organic Synthesis, Leiden Institute of Chemistry (LIC), Leiden University , P.O. Box 9502, 2300RA Leiden,…. Hauptthemen laut MEDLINE: Aziridines, Brain, Enzyme Inhibitors, Cyclitols. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia, Innovaci??n y Universidades, HORIZON EUROPE Marie Sklodowska-Curie Actions, Royal Society.
Abstract (Originalsprache)
Neutral glucosylceramidase GBA2 is a retaining β-d-glucosidase involved in sphingolipid metabolism and implicated in neurological lysosomal storage disorders, yet the lack of highly selective chemical inhibitors has hindered efforts to disentangle its function from that of glucosylceramide synthase (GCS) and lysosomal glucosylceramidase (GBA1). Here, we report the development of the first brain-penetrant, covalent inhibitor that selectively inactivates GBA2 in vivo. Building on β-d-arabinofuranose-configured (β-d-Araf) cyclitol aziridine activity-based probes previously shown to covalently and selectively label GBA2, we designed and synthesized a focused library of electrophile-bearing cyclitols, including epoxides, cyclic sulfates, and a diverse set of N-alkyl aziridines. Biochemical evaluation of their inhibitory activity against GBA1, GBA2, GBA3 and GCS revealed that several N-alkyl aziridines are highly selective, nanomolar GBA2 inhibitors. Lead compounds also demonstrated metabolic stability in murine plasma, robust cellular activity and high selectivity in living cells, with no detectable GCS inhibition. Notably, octyl-alkyne aziridine 5 selectively inhibited GBA2 in mouse brain, representing the first covalent GBA2 inhibitor with demonstrated in vivo activity and brain permeability. Together, these results establish β-d-Araf cyclitol aziridine 5 as a versatile inhibitor for selective, covalent GBA2 inhibition, well suited to dissect GBA2 biology in vivo, particularly in neurological lysosomal storage disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departments of Medical Biochemistry and Bio-organic Synthesis, Leiden Institute of Chemistry (LIC), Leiden University , P.O. Box 9502, 2300RA Leiden, The Netherlands.
- Departament de Química Inorgànica i Orgànica (Secció de Química Orgànica) and Institut de Química Teòrica i Computacional (IQTCUB), Universitat de Barcelona, Martí i Franquès 1, 08028Barcelona, Spain.
- Department of Chemistry, York Structural Biology Laboratory, University of York, Heslington, YorkYO10 5DD, U.K.
- Department of Medical Biochemistry, Amsterdam University Medical Center, location Academic Medical Center, University of Amsterdam, Amsterdam1105AZ, The Netherlands.
- Amsterdam Gastroenterology, Endocrinology, and Metabolism Institute, Amsterdam University Medical Center, Amsterdam1105AZ, The Netherlands.
- Amsterdam Cardiovascular Sciences Institute, Amsterdam University Medical Center, Amsterdam1105AZ, The Netherlands.
ORCID-Profile: Wendy A Offen, Florian Küllmer, Noam Zelcer, Gideon J Davies, Carme Rovira, Herman S Overkleeft, Johannes M F G Aerts, Marta Artola
Förderung
- Ministerio de Ciencia, Innovaci??n y Universidades
- HORIZON EUROPE Marie Sklodowska-Curie Actions
- Royal Society
- European Commission
- Ministerio de Econom??a y Competitividad
Zitieren
APA
Lammers, R. F., Su, Q., Mazo, L., A Offen, W., Ottenhoff, R., Bulterman, M. J., van der Lienden, M., Ferraz, M. J., Küllmer, F., Ilhan, Z., van den Elst, H., van der Made, I., van Roomen, C. P. A. A., de Jongh, A., van den Nieuwendijk, A. M. C. H., Boot, R. G., Zelcer, N., Davies, G. J., Rovira, C., …, & Artola, M. (2026). β- d -Arabinofuranose-configured Cyclitol Aziridines as Selective, Brain-penetrant Covalent GBA2 Inhibitors. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.6c09754
Vancouver
Lammers RF, Su Q, Mazo L, A Offen W, Ottenhoff R, Bulterman MJ, et al. β- d -Arabinofuranose-configured Cyclitol Aziridines as Selective, Brain-penetrant Covalent GBA2 Inhibitors. Journal of the American Chemical Society. 2026. doi:10.1021/jacs.6c09754
BibTeX
@article{Lammers2026,
author = {Lammers, Rob F and Su, Qin and Mazo, Laura and A Offen, Wendy and Ottenhoff, Roelof and Bulterman, Mats J and van der Lienden, Martijn and Ferraz, Maria J and Küllmer, Florian and Ilhan, Zahid and van den Elst, Hans and van der Made, Ingeborg and van Roomen, Cindy P A A and de Jongh, Anne and van den Nieuwendijk, Adrianus M C H and Boot, Rolf G and Zelcer, Noam and Davies, Gideon J and Rovira, Carme and Overkleeft, Herman S and Aerts, Johannes M F G and Artola, Marta},
title = {β- d -Arabinofuranose-configured Cyclitol Aziridines as Selective, Brain-penetrant Covalent GBA2 Inhibitors},
journal = {Journal of the American Chemical Society},
year = {2026},
doi = {10.1021/jacs.6c09754}
}
EUVIMED